Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD 12.17
-0.17 (-1.38%)
Sep 25, 2026, 10:30 AM EST
Satellos Bioscience Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
261.81M CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Satellos Bioscience News
- 1 day ago - Satellos announces U.S. FDA cleared IND application for forazapadin - TheFly
- 1 day ago - Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - GlobeNewsWire
- 9 days ago - Satellos Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 10 days ago - Satellos to Present at the 31st Annual Congress of the World Muscle Society - GlobeNewsWire
- 15 days ago - Satellos Bioscience Slides: Corporate presentation - Filings
- 15 days ago - Satellos Bioscience Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 16 days ago - Satellos Bioscience (MSLE) Gains INN for Forazapadin Amid Unprofitable Status and Mixed Market ... - GuruFocus
- 16 days ago - Satellos Names Forazapadin As INN For Lead DMD Drug Candidate - Nasdaq